C4 Therapeutics, Inc. (CCCC)

Over the past six months, C4 Therapeutics' stock (CCCC) has experienced several notable events. The stock was trading at $1.91 at the beginning of 2026 and has since increased by 54.5% to $2.95 as of May 9, 2026. Key events include an expanded partnership with Roche focused on Degrader-Antibody Conjugates (DACs) for cancer treatment, the first patient dosed in a Phase 1b trial of Cemsidomide, the release of Q4 2025 financial results exceeding analysts' expectations, the first patient dosed in the Phase 2 MOMENTUM trial, a clinical trial collaboration with Pfizer Inc., and a stock tumble of -11.3% amidst negative market sentiment.

Information regarding specific "demand seasonality" for C4 Therapeutics, Inc.'s products and services is not available in the provided search results. As a clinical-stage biopharmaceutical company, traditional demand seasonality does not typically apply to C4 Therapeutics at its current stage. The demand for its future products, if approved, would likely be driven by disease prevalence, treatment efficacy, and market access rather than seasonal fluctuations.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted protein degraders using its proprietary Controlled Inducible Degradation (CiD) platform, also known as the TORPEDO® platform. The company's pipeline includes small-molecule degrader candidates like Cemsidomide (CFT7455) for multiple myeloma and CFT8919 for non-small cell lung cancer, along with other discovery products. C4 Therapeutics has established collaborations with major pharmaceutical partners to advance its CiD platform and develop novel degrader molecules.

C4 Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States. The company's operations and collaborations suggest a focus within the global biopharmaceutical landscape, particularly through its partnerships with international pharmaceutical companies.

C4 Therapeutics is recognized as a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science. Its strategic collaborations with major pharmaceutical companies suggest a positive standing within the industry. Analyst consensus rates C4 Therapeutics as a "Moderate Buy," with a generally favorable view from financial analysts regarding the company's prospects. Positive data from clinical trials and the expanded partnership with Roche contribute positively to its reputation, while negative profit margins and a stock tumble could raise concerns.

The ownership structure of C4 Therapeutics (CCCC) stock includes institutional, retail, and individual investors. Approximately 27.58% of the company's stock is owned by Institutional Investors, 3.36% by Insiders, and 69.06% by Public Companies and Individual Investors. Major institutional shareholders include Point72 Asset Management, L.P., Morgan Stanley, and RA Capital Management, L.P. Marc A. Cohen is the largest individual shareholder, owning 8.31 million shares, representing 8.52% of the company.